Clinical Trial: Mycapssa® (octreotide capsules) for Neuroendocrine Tumours

Clinical Trial: Mycapssa® (octreotide capsules) for Neuroendocrine Tumours

Clinical Trials, Treatment
The delayed-release capsules contain 20mg of octreotide. The mainstay somatostatin analogues for Neuroendocrine Tumour patients are Lanreotide and Octreotide and I have blogged or mentioned them frequently, and they are probably two of the most written words in my private patient group ....... coupled with "injection" or "shot".  For years, people have talked about the need for different delivery systems including capsules and even nasal sprays.  Many patients have indicated a preference for an easier route into the system with similar efficacy.  I have been following a few of these initiatives in an article called "Somatostatin Analogues and delivery methods in the pipeline".  While generic somatostatin analogues have helped people and organisations with cost, these generics are still using injection delivery systems. Two diseases in particular have been benefitting for some…
Read More
Somatostatin Analogues and delivery methods in the pipeline

Somatostatin Analogues and delivery methods in the pipeline

Awareness, Clinical Trials, Living with Neuroendocrine Cancer
This is my live blog post covering new developments in the area of new Somatostatin Analogues and new delivery systems.  Abstract As most of you will be aware, there are currently two main types of Somatostatin Analogues (SSA) in use for the treatment of mainstream Neuroendocrine Tumours (NETs) - Octreotide and Lanreotide.  You can click on the links for information on both of these well-known NET treatments.  This post will focus on the not so well known and anything in the pipeline including different delivery systems. Those who have read the Octreotide/ Lanreotide patient leaflets will know those SSAs are also used in the treatment of a condition known as Acromegaly. You can see why the drug is used for both as they control the release of excess secretions of…
Read More